Ogsiveo 150 MG Tablet 7-Day 14 Count Pack

RxCUI
2680370
RxNorm name
Ogsiveo 150 MG Tablet 7-Day 14 Count Pack
Display name
Ogsiveo 150 MG Tablet 7-Day 14 Count Pack
Full name
Ogsiveo 150 MG Tablet 7-Day 14 Count Pack
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:27

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
OGSIVEONIROGACESTATSpringWorks Therapeutics, Inc.f172e6ff-3190-41b0-b95a-58a7ef9e9e1e2026-03-26Warnings, Adverse reactionsExact identifier
rxcui: 2680370

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
f172e6ff-3190-41b0-b95a-58a7ef9e9e1eOgsiveo 150 MG Tablet 7-Day 14 Count PackPSN14These highlights do not include all the information needed to use OGSIVEO safely and effectively. See full prescribing information for OGSIVEO. OGSIVEO ® (nirogacestat) tablets, for oral use Initial U.S. Approval: 202320260326
f172e6ff-3190-41b0-b95a-58a7ef9e9e1eOgsiveo 150 MG Tablet 7-Day 14 Count PackSY14These highlights do not include all the information needed to use OGSIVEO safely and effectively. See full prescribing information for OGSIVEO. OGSIVEO ® (nirogacestat) tablets, for oral use Initial U.S. Approval: 202320260326
f172e6ff-3190-41b0-b95a-58a7ef9e9e1e{14 (nirogacestat 150 MG Oral Tablet [Ogsiveo]) } Pack [Ogsiveo 150 MG 7-Day]BPCK14These highlights do not include all the information needed to use OGSIVEO safely and effectively. See full prescribing information for OGSIVEO. OGSIVEO ® (nirogacestat) tablets, for oral use Initial U.S. Approval: 202320260326